Tissue Regenix Group (TRX)

Sector:

Financials

Index:

FTSE AIM All-Share

 61.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 71.50p
  • 52 Week Low: 49.00p
  • Currency: UK Pounds
  • Shares Issued: 70.57m
  • Volume: 944
  • Market Cap: £43.40m
  • RiskGrade: 22
  • Beta: 0.00

Mike Barker installed as finance chief at Tissue Regenix

By Josh White

Date: Wednesday 28 Aug 2019

LONDON (ShareCast) - (Sharecast News) - Regenerative medical devices company Tissue Regenix Group announced the appointment of Mike Barker as its chief financial officer on Wednesday.
The AIM-traded firm said Barker would join the group as CFO and as an executive director on the board with immediate effect, having supported the company since the beginning of the year as interim finance director.

It said Barker, a Chartered Accountant for more than 20 years, was bringing experience of both AIM-listed and private businesses with him.

After training with Deloitte, he reportedly spent 10 years in its corporate finance advisory business working on private equity transactions, before setting up his own consultancy business to assist small to medium enterprises in the delivery of strategic plans.

During that time, Tissue Regenix said he worked "closely" with the management team of Quantum Pharma - a UK manufacturer and supplier of unlicensed medicines and hard-to-source products, acquired by Clinigen Group in 2017, to deliver strategic projects before holding the position of group corporate development director.

"It's a pleasure to welcome Mike to the executive team," said executive director John Samuel.

"He is well acquainted with the business, having supported the group since the beginning of the year.

"His experience in AIM listed businesses and contribution to strategic planning will augment and strengthen our management and executive teams as we continue to improve the efficiency of our operations across the business to meet the increasing demand for our products."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

TRX Market Data

Currency UK Pounds
Share Price 61.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 71.50p
52 Week Low 49.00p
Volume 944
Shares Issued 70.57m
Market Cap £43.40m
Beta 0.00
RiskGrade 22

TRX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
42.03% below the market average42.03% below the market average42.03% below the market average42.03% below the market average42.03% below the market average
61.11% below the sector average61.11% below the sector average61.11% below the sector average61.11% below the sector average61.11% below the sector average
Price Trend
61.18% above the market average61.18% above the market average61.18% above the market average61.18% above the market average61.18% above the market average
39.66% above the sector average39.66% above the sector average39.66% above the sector average39.66% above the sector average39.66% above the sector average
Income Not Available
Growth
20.26% above the market average20.26% above the market average20.26% above the market average20.26% above the market average20.26% above the market average
17.43% above the sector average17.43% above the sector average17.43% above the sector average17.43% above the sector average17.43% above the sector average

TRX Dividends

No dividends found

Trades for 03-May-2024

Time Volume / Share Price
08:42 944 @ 61.05p

TRX Key Personnel

CEO Daniel Lee
CFO David Cocke

Top of Page